TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be included if they are presenting for elective cardiac surgery using cardiopulmonary bypass and are 180 days of age or less.~Exclusion Criteria:~Sensitivity to ATIII product (Thrombate, Grifols, Los Angeles, CA)~* Known inherited or acquired coagulation defect~* Current or prior treatment with pro-or anticoagulant medication within past 30 days (except aspirin or a single dose of heparin, e.g. for catheterization)~* Known central venous thrombosis~* Recent (30 days) transfusion with hemostatic blood products (fresh-frozen plasma, platelets, cryoprecipitate, whole blood)~* wt less than 3000g

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 180 Days
- Healthy Volunteers: f

Study Arms:
- Antithrombin III (Type: ACTIVE_COMPARATOR): Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a.
- Placebo (Type: PLACEBO_COMPARATOR): placebo (normal saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists, or a diagnosis of axial spondyloarthritis (axSpA) with a pelvis MRI with significant bone marrow edema on STIR sequences;~* Minimum of 18 years old;~* Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in the past month) and willing to withhold medication for one week; or having active symptoms that require initiation of NSAIDs;~* Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past three months;~* Have active disease after initial washout period, defined by BASDAI \>=4/10, or back pain numerical rating scale (NRS)\>=4/10~Exclusion Criteria:~* Patients who have concurrent rheumatic diseases other than AS or axSpA;~* Patients who have oral corticosteroid in the past two weeks; patients who have acute peripheral arthritis;~* Patients with a fibromyalgia score \>= 13;~* Patient with extensive cardiac history, history of gastrointestinal bleeding that required blood transfusion, chronic kidney diseases, abnormal liver function tests; or female patients who are pregnant.~Use of low-dose of aspirin (\<100mg daily) is allowed in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: ACTIVE_COMPARATOR): Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
- Diclofenac (Type: ACTIVE_COMPARATOR): Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
- Meloxicam (Type: ACTIVE_COMPARATOR): Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
- Celecoxib (Type: ACTIVE_COMPARATOR): Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing percutaneous coronary balloon angioplasty and stenting~* Ages 18 years and older~* TIMI III flow on the initial angiography~* Native coronary artery lesions~Exclusion Criteria:~* Patients unable to give consent~* Adenosine allergy~* Severe asthma with bronchial reactivity~* Cardiogenic or circulatory shock~* Acute or chronic total coronary artery occlusions~* Patients requiring Rotablator therapy~* In stent restenosis~* Second or third degree AV block without a permanent pacemaker~* ST-Elevation MI~* Elevated baseline CK/ CK-MB or troponin levels (Pre-existing Non-STemi)~* Current pregnancy~* Patients not already on statin therapy or intolerant of statins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
- 2 (Type: OTHER): Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 7 to \<13 years~* Amblyopia associated with anisometropia, strabismus (comitant or incomitant), or both at the time of the eligibility examination~* Visual acuity in the amblyopic eye between 49 and 71 letters inclusive (20/40 to 20/100 inclusive) on the eETDRS~* Visual acuity in the sound eye of 79 or more letters on the eETDRS (20/25 or better)~* Inter-eye acuity difference of 15 or more letters (3 or more logMAR lines)~* At least 800 seconds of arc on the Randot Preschool Stereoacuity Test~* Previous or current amblyopia treatment with spectacles or contact lenses, patching or atropine is permitted.~* No myopia more than -6.00 D spherical equivalent in the amblyopic eye~* Single vision spectacles, if needed, worn for at least 16 weeks or until visual acuity documented to be stable~* The child has access to a computer on a daily basis (to use the home vision therapy software)~Exclusion Criteria:~* Previous vision therapy or orthoptics~* Known skin reactions to patch or bandage adhesives~* Prior intraocular or refractive surgery~* Bifocals~* Constant strabismus at near at the eligibility examination~* A family member is (or has been) enrolled in this study

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): 2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
- Control (Type: SHAM_COMPARATOR): 2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Normal Multichannel Intraluminal Impedance (MII)-pH Parameters for Today's Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female adults between the ages of 33-65~* BMI range of 23.9 - 38.9~* Ability to give consent to participate in study~Exclusion Criteria:~* History of extraesophageal reflux disease symptoms such as chronic or acute cough and/or throat clearing and /or non-cardiac chest pain.~* History of gastroesophageal reflux disease (GERD) such as heartburn and/or regurgitation.~* History of proton pump inhibitor (PPI) usage ten days prior to the procedure (MII-pH) or H2RA's two days prior to MII-pH and antacids usage on the procedure day.~* History of thoracic, gastric or esophageal surgery.~* Histories of Diabetes Mellitus, neurological disorders, gastrointestinal disease, taking medication that alter the intragastric acidity or esophageal motility.~* Pregnancy or nursing mothers.~* Alcohol consumption \>40g/day, smoking \>10cigarettes/day.

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Volunteers (Type: EXPERIMENTAL): Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Mid-Life Adiposity in Functional Brain Connectivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 45-65 years of age~* Normal memory~* Right-handed~* General good physical health~Exclusion Criteria:~* History of stroke or neurological disease~* Seizures or head injury with loss of consciousness within the last five years~* Ferrous (magnetic) or electronic implants (due to the magnet in the MRI scanner)~* Claustrophobia~More detailed inclusion/exclusion criteria must be met in order to qualify for the study. The study coordinator will determine eligibility.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form~* A diagnosis of pancreatic ductal adenocarcinoma~Exclusion Criteria:~* Patients unable to provide informed consent~* Women who are pregnant or intending to become pregnant during the study~* Patients with body mass index greater than 40 kg/m\^2~* History of severe allergic-like reaction to iodinated contrast media

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (CT perfusion sequence) (Type: EXPERIMENTAL): Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe COPD~* Smoking history of greater or equal to 10 pack-years~* Diagnosis of stable moderate to severe COPD as defined by the GOLD Guidelines~* Postbronchodilator FEV1 from 30% to 79% of predicted values, inclusive~* Postbronchodilator FEV1/FVC ratio \< 0.70~Exclusion Criteria:~* History or presence of asthma, allergic rhinitis, or exercise-induced bronchospasm~* Hospitalization for an acute COPD exacerbation in the 3 months prior to study entry~* Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry~* Eosinophil count of at least 600 cells/mm3~* Long term oxygen therapy \> 15 hours a day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Once-daily aclidinium/formoterol (Type: EXPERIMENTAL): Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
- Morning aclidinium/formoterol plus evening formoterol (Type: EXPERIMENTAL): Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
- Formoterol BID (Type: ACTIVE_COMPARATOR): Formoterol fumarate 12 µg twice-daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is taking a stable daily dose of opioids of ≥30-mg morphine-equivalent total daily dose (METDD) for chronic non-cancer pain~* Has constipation that is caused by the chronic use of opioids~* Is willing to use only the study-provided laxative(s) and to discontinue use of all other laxatives, enemas, stool softeners, and other medications to treat constipation (for example, lubiprostone) during the study period (from Screening until the last study assessment).~* Is able and willing to refrain from facilitating defecation via manual maneuvers (for example, digital evacuation or support of the pelvic floor) during the study period (from Screening to the last study assessment)~Exclusion Criteria:~* Has gastrointestinal (GI) or pelvic disorders known to affect bowel transit (for example, obstruction) or contribute to bowel dysfunction~* Has evidence of intestinal obstruction~* Has a history of rectal bleeding not due to hemorrhoids or fissures~* Has an active malignancy of any type (participants with a history of successfully treated malignancy \>5 years before the scheduled administration of study medication and participants with treated basal or squamous cell cancer may be enrolled)~* Is taking antispasmodics (for example, dicyclomine), antidiarrheals (for example, loperamide), prokinetics (for example, metoclopramide), or locally acting chloride channel activators (for example, lubiprostone)~* Is taking non-opioid medications known to cause constipation (for example, iron sulfate therapy or tricyclic antidepressants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CB-5945 (Type: EXPERIMENTAL): 0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, administered orally, BID for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Signed informed consent~* All cases of suspected MRSA bacteremia as determined by a patient with at least one blood culture growing gram-positive cocci in clusters with a clinical syndrome consistent with true bacteremia including fever, hypothermia (temperature \< 36.0º C), tachycardia (heart rate \> 100 beats/minute), hypotension (systolic blood pressure \< 90 mm Hg) or other clinical features of sepsis.~* All cases of right-sided native valve endocarditis due to MRSA~* Patients who are diagnosed with left-sided native valve endocarditis after randomization will be continued in the study~* Patients with MRSA bacteremia associated with infected foreign bodies, including vascular prostheses, orthopedic prostheses

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose vancomycin (Type: ACTIVE_COMPARATOR): Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
- High-dose daptomycin (Type: EXPERIMENTAL): Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: User Evaluation Study of SyncVision System With Software v4.X

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible and indicated for cardiac catheterization and pressure-wire assessment in the coronary arteries as per standard hospital practice~* Males over the age of 18 years and post-menopausal females~* Patient is able to give written informed consent prior to using his/her study data for evaluation and documentation~Exclusion Criteria:~- Patient is unable to give written informed consent prior to using his/her study data for evaluation and documentation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: None): This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Idiopathic Pulmonary Fibrosis: a Case-control Study

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject with wide neck intracranial aneurysm located at a bifurcation~2. The subject is between 18 and 80 years of age the time of consent~3. Informed consent is obtained and the subject signs the IRB approved consent prior to beginning any study procedures~4. In the opinion of the treating physician, placement of the PulseRider® device is technically feasible and clinically indicated~Exclusion Criteria:~1. Unstable neurological deficit (condition worsening within the last 90 days)~2. Subarachnoid Hemorrhage (SAH) within the last 60 days~3. Irreversible bleeding disorder~4. Patient has another intracranial aneurysm that in the Investigator's opinion, may require treatment within the 1 year follow up period~5. A history of contrast allergy that cannot be medically controlled~6. Known allergy to nickel~7. Relative contraindication to angiography~8. Woman of child-bearing potential who cannot provide a negative pregnancy test~9. Current involvement in a study for another investigational product~10. Patient and / or family considering a move from this geographical location at the time of consent~11. Categorized as a vulnerable population and require special treatment with respect to safeguards of well-being (e.g. cognitively impaired, veteran, prisoner, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Continuous Intraarticular Infusion in Patients Undergoing Arthroscopic Knee and Shoulder Operations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children between the ages of 11 and 19 years old.~* Knee and shoulder arthroscopy procedures~Exclusion Criteria:~* Contraindications to Femoral-Interscalene Nerve Block~* Conditions that affect the proper evaluation of pain and side effects.~* Intake of NSAIDs or opioids in the 12 hours prior to the operation~* Allergy to study medications

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy